<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247974</url>
  </required_header>
  <id_info>
    <org_study_id>08-PR-1006</org_study_id>
    <nct_id>NCT01247974</nct_id>
  </id_info>
  <brief_title>Evaluation Of New Onset Postoperative Atrial Fibrillation</brief_title>
  <official_title>Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM® for Pericardial Closure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziyo Biologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aziyo Biologics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, randomized and controlled clinical trial comparing the
      safety and efficacy of the CorMatrix ECM for Pericardial Closure to reduce the incidence of
      new onset postoperative atrial fibrillation by circumferentially reconstructing the normal
      pericardial anatomy following isolated, first-time, CABG procedures compared to subjects that
      do not undergo pericardial closure. This trial will be conducted at up to 20 clinical sites
      in the U.S.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this prospective clinical trial is to demonstrate the safety and efficacy of
      the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative
      atrial fibrillation by circumferentially reconstructing the normal pericardial anatomy
      following isolated, first-time, coronary artery bypass grafting (CABG) procedures as compared
      to subjects who did not undergo pericardial closure. Safety will be established by
      demonstrating that the composite clinical event rate for the ECM treatment group is not worse
      than the control group that did not undergo pericardial closure. The efficacy will be
      established by demonstrating a reduced incidence of new onset postoperative atrial
      fibrillation in the ECM treatment group as compared to the control group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days postprocedure</time_frame>
    <description>A composite endpoint consisting of the following procedure- related serious adverse events occurring within 30 days postprocedure:
Death
Myocardial Infarction (MI)
Stroke
Mediastinal Reoperation
Percutaneous Coronary Intervention (PCI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint</measure>
    <time_frame>7 days postoperatively or hospital discharge, whichever is sooner</time_frame>
    <description>Rate of new onset postoperative atrial fibrillation during the first seven days postoperatively or prior to hospital discharge, whichever was sooner.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">439</enrollment>
  <condition>Atrial Fibrillation New Onset</condition>
  <arm_group>
    <arm_group_label>CorMatrix ECM for Pericardial Closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pericardial closure with CorMatrix ECM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Pericardial Closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorMatrix ECM for Pericardial Closure</intervention_name>
    <description>Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure</description>
    <arm_group_label>CorMatrix ECM for Pericardial Closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is 18 years of age or older

          -  This cardiac operation is the subject's first or primary cardiac operation

          -  The subject must be undergoing an isolated CABG procedure using a median sternotomy
             approach

          -  The subject must possess the ability to provide written Informed Consent

          -  The subject must express a willingness to fulfill all of the expected requirements of
             this clinical protocol

        Exclusion Criteria:

          -  Prior history of atrial fibrillation

          -  Prior history of open heart surgery

          -  Prior history of pericarditis

          -  Prior history of anti-arrhythmia drug treatment (e.g., amiodarone, dronedarone or
             sotalol) in the past six months

          -  The subject has an implantable cardiac device (i.e., cardiac resynchronization therapy
             devices with and without defibrillator capabilities (CRTs and CRT-Ds), implantable
             cardioverter-defibrillators (ICD) and pacemakers)

          -  Concomitant procedure planned

          -  In the investigator's opinion, the subject may require prophylactic treatment with
             anti-arrhythmia drugs or temporary pacing postoperatively
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Gerdisch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Francis Heart Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trinity Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Alabama Medical Center</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mobile Infirmary Medical Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Agnes Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Heart Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>February 13, 2014</results_first_submitted>
  <results_first_submitted_qc>August 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2015</results_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Bypass Grafting</keyword>
  <keyword>New Onset Postoperative Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One subject, Subject 011-006, was randomized in error to the ECM treatment group, but did not provide informed consent. This deviation was discovered prior to the surgery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CorMatrix® ECM®</title>
          <description>CorMatrix® ECM® for Pericardial Closure: Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Pericardium is not closed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CorMatrix® ECM®</title>
          <description>CorMatrix® ECM® for Pericardial Closure: Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No closure of pericardium</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="217"/>
            <count group_id="B2" value="222"/>
            <count group_id="B3" value="439"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18Y and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint</title>
        <description>A composite endpoint consisting of the following procedure- related serious adverse events occurring within 30 days postprocedure:
Death
Myocardial Infarction (MI)
Stroke
Mediastinal Reoperation
Percutaneous Coronary Intervention (PCI)</description>
        <time_frame>30 days postprocedure</time_frame>
        <population>Performed with the FAS population using multiple imputation methods to impute values for missing or incomplete data. FAS population was defined as subjects in the ITT population who had CABG surgery and received their assigned treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>CorMatrix ECM for Pericardial Closure</title>
            <description>Pericardial closure with CorMatrix ECM</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Pericardial Closure</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint</title>
          <description>A composite endpoint consisting of the following procedure- related serious adverse events occurring within 30 days postprocedure:
Death
Myocardial Infarction (MI)
Stroke
Mediastinal Reoperation
Percutaneous Coronary Intervention (PCI)</description>
          <population>Performed with the FAS population using multiple imputation methods to impute values for missing or incomplete data. FAS population was defined as subjects in the ITT population who had CABG surgery and received their assigned treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Effectiveness Endpoint</title>
        <description>Rate of new onset postoperative atrial fibrillation during the first seven days postoperatively or prior to hospital discharge, whichever was sooner.</description>
        <time_frame>7 days postoperatively or hospital discharge, whichever is sooner</time_frame>
        <population>Primary analysis was based upon the ITT population using multiple imputation to impute missing values. The ITT population was defined as all subjects who provided informed consent and were randomized in the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>CorMatrix ECM for Pericardial Closure</title>
            <description>Pericardial closure with CorMatrix ECM</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Pericardial Closure</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Effectiveness Endpoint</title>
          <description>Rate of new onset postoperative atrial fibrillation during the first seven days postoperatively or prior to hospital discharge, whichever was sooner.</description>
          <population>Primary analysis was based upon the ITT population using multiple imputation to impute missing values. The ITT population was defined as all subjects who provided informed consent and were randomized in the trial.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>The adverse events are summarized using the Full Analysis Set population, which includes 428 subjects (208 subjects in the ECM group and 220 subjects in the control group. AEs were only collected from the treated population.</desc>
      <group_list>
        <group group_id="E1">
          <title>CorMatrix ECM</title>
          <description>CorMatrix ECM for Pericardial Closure</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Pericardium is not closed</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA SOC</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Event led to Death</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA SOC</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multi-site publication is not submitted within twenty-four (24) months after conclusion of the Study at all sites, Institution and/or the Principal Investigator may publish the results from Institution’s site individually, subject to Sponsor’s rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>CorMatrix Cardiovascular</organization>
      <phone>6785662628</phone>
      <email>agreen@cormatrix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

